title: Cabergoline-induced psychotic exacerbation in schizophrenic patients.
abstract: BACKGROUND
  Hyperprolactinemia is a well-recognized side effect of antipsychotic treatment. Cabergoline, a dopamine agonist, has been introduced on the market to treat hyperprolactinemia, even secondary to antipsychotic use.
  
  
  METHODS
  In this article, we described two schizophrenic patients who received cabergoline to treat their antipsychotic-induced hyperprolactinemia and developed a subsequent psychotic exacerbation. The first patient received amisulpride as antipsychotic medication, and the second one took risperidone and fluoxetine for her psychotic and depressive symptoms, respectively. Both patients improved significantly their psychotic symptoms in 1 week without changing their former antipsychotic regimens.
  
  
  CONCLUSIONS
  To the best of our knowledge, we found no previous report of cabergoline-induced psychotic exacerbation in schizophrenic patients who received antipsychotics. We brought up questions whether schizophrenic patients on amisulpride or with the addition of fluoxetine may have higher risk to experience psychotic worsening. We also highlighted the possible role of dose-dependent nature in cabergoline-induced psychotic exacerbation, suggesting that the single starting dose of 0.5 mg or higher might be unsafe in schizophrenic patients.
  
  
  CONCLUSIONS
  These cases suggest that cabergoline, like other dopaminergic agents, should be used with caution in psychotic patients and the dose should be as low as possible.
authors.affiliation: Department of Psychiatry, Taipei Medical University-Wan Fang Medical Center, Taipei, Taiwan.
authors.forename: Shen-Chieh
authors.initials: SC
authors.lastname: Chang
authors.forename: Chun-Hsin
authors.initials: CH
authors.lastname: Chen
authors.forename: Mong-Liang
authors.initials: ML
authors.lastname: Lu
mesh_terms: D000208:Acute Disease; D000328:Adult; D000077582:Amisulpride; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004873:Ergolines / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005473:Fluoxetine / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D006966:Hyperprolactinemia / Q000139:chemically induced* / Q000188:drug therapy*; D011605:Psychoses, Substance-Induced / Q000175:diagnosis / Q000209:etiology*; D018967:Risperidone / Q000009:adverse effects / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D013469:Sulpiride / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D014150:Antipsychotic Agents; D018491:Dopamine Agonists; D004873:Ergolines; D005473:Fluoxetine; D013469:Sulpiride; D000077582:Amisulpride; D018967:Risperidone; D000077465:Cabergoline